Bupivacaine

證據等級: L5

預測適應症: 4 個

Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans

One-Sentence Summary

Bupivacaine is a long-acting amide-type local anesthetic widely used in regional and neuraxial anesthesia. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans (ACA), however no clinical trials and no supporting publications were identified, placing this prediction at the lowest evidence tier.

Quick Overview

Item	Content
Original Indication	Local anesthesia (no US FDA NDA found in dataset)
Predicted New Indication	Acrodermatitis Chronica Atrophicans
TxGNN Prediction Score	99.23%
Evidence Level	L5
US Market Status	Not found in dataset (0 NDAs on record)
Number of NDAs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Bupivacaine is a long-acting amide-class local anesthetic. Its primary mechanism of action is voltage-gated sodium channel (Nav1.x) blockade, which prevents depolarization of neuronal cell membranes and thereby interrupts peripheral nerve conduction. It is routinely used for infiltration anesthesia, nerve blocks, epidural, and spinal anesthesia.

Acrodermatitis Chronica Atrophicans (ACA) is a late-stage cutaneous manifestation of Lyme disease caused by Borrelia burgdorferi sensu lato infection, characterized by progressive fibrotic skin atrophy predominantly on the extremities. The standard of care is prolonged antibiotic therapy (doxycycline or amoxicillin), not sodium channel modulation. There is no established direct mechanistic link between bupivacaine’s primary pharmacology and ACA pathophysiology.

The most plausible — yet highly speculative — connection is bupivacaine’s secondary anti-inflammatory activity at supratherapeutic concentrations: amide local anesthetics have been shown in vitro to suppress NLRP3 inflammasome activation and reduce IL-1β/IL-6 secretion. TxGNN likely captured this indirect anti-inflammatory signal within its knowledge graph. However, the biological distance between this weak immunomodulatory effect and the infection-driven, fibrotic immune pathology of ACA is substantial. This prediction should be treated as a computational hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered for Bupivacaine × Acrodermatitis Chronica Atrophicans.

Literature Evidence

Currently no related literature available for Bupivacaine × Acrodermatitis Chronica Atrophicans.

Additional TxGNN Predictions (Ranks 2–4)

The top four predicted indications all cluster within autoimmune/connective-tissue inflammatory disease space, suggesting TxGNN has captured a shared feature pattern rather than disease-specific signals.

Rank	Disease	Score	Evidence	Shared Mechanistic Hypothesis
2	Neonatal Dermatomyositis	99.15%	L5 — no trials, no literature	NLRP3/anti-inflammatory signal; severe LAST risk in neonates
3	Childhood ILD (connective tissue–associated)	99.11%	L5 — no trials, no literature	In vitro fibroblast inhibition at supraclinical doses
4	Amyopathic Dermatomyositis	99.03%	L5 — no trials, no literature	Shares dermatomyositis cluster with rank 2

All rank 2–4 predictions carry the same Hold recommendation and the same absence of confirmatory evidence.

Safety Considerations

Please refer to the package insert for safety information.

Note for evaluation teams: The TFDA/FDA package insert warnings and contraindications were not retrieved in this data pull (Data Gap DG001). Given that bupivacaine carries a well-documented risk of Local Anesthetic Systemic Toxicity (LAST) — including cardiac arrhythmia and CNS seizures — any repurposing application requiring systemic exposure must undergo a dedicated safety review before proceeding. This risk is especially pronounced in neonates (rank 2 indication), where therapeutic margins are extremely narrow.

Conclusion and Next Steps

Decision: Hold

Rationale: All four predicted indications sit at Evidence Level L5 (model prediction only), with zero supporting clinical trials or peer-reviewed publications for any drug–disease pair. The mechanistic link between bupivacaine’s sodium channel blockade and these autoimmune/infectious dermatological conditions is highly indirect and based on speculative extrapolation from in vitro anti-inflammatory data at supraclinical doses.

To revisit this candidate, the following would be needed:

MOA gap closure (DG002): Retrieve full DrugBank pharmacology record to determine whether any approved secondary targets (e.g., TRPV1, inflammatory signaling) provide a more credible link to ACA or dermatomyositis
Preclinical signal search: Systematic literature search for bupivacaine in Lyme disease, NLRP3-driven fibrosis, or dermatomyositis animal models
Safety baseline (DG001): Retrieve and parse FDA package insert to document contraindications and systemic toxicity profile before any new indication exploration
US registration verification: Confirm actual US FDA marketing status — bupivacaine is a widely used anesthetic and its absence from the dataset (0 NDAs) likely reflects a data pipeline gap rather than a true regulatory gap
Mechanistic plausibility gate: If any preclinical signal is found, conduct a formal mechanistic plausibility assessment (e.g., NLRP3 inhibition potency vs. clinically achievable plasma concentrations) before any IND-enabling studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.